Vital Images, Inc. Receives 510(k) Clearance for Image Denoising Software

MINNEAPOLIS, Aug. 18, 2014 -- Vital Images, Inc. ("Vital"), a Toshiba Medical Systems Group Company, received 510(k) clearance from the U.S. Food and Drug Administration for Image Denoising software, a post-processing filter designed to be used in conjunction with original image data used with its Vitrea® software.

Vital's denoising filter, Structure Preserving Diffusion (SPD), focuses on increasing image quality by improving the appearance of noisy images for CT and X-ray Angiography. It addresses the noise challenges presented by today's CT protocols. SPD can be used with any scanner generation in conjunction with iterative reconstruction (IR) techniques to enhance diagnostic interpretation. Denoising filters are applied in all available viewports, i.e. MPR (multi-planar reformat), CPR (curved planar reformat), 3D and other volumetric views.  Denoised series can then be stored with the original source images in picture archiving and communication systems (PACS).  Built to work with existing hardware, users have the ability to create and save their own denoising filters. 

"Image Denoising helps customers see a clear view of anatomy from noisy scans without changing the integrity of the image," said Jim Litterer, General Manager at Vital. "In terms of efficiency and productivity, denoising is a game-changer. Technologists no longer have to spend hours sorting through the noise to get clear images."

Image Denoising is available in the U.S. in Vitrea version 6.6.3 and in previous Vitrea versions in other countries globally.

About Vital Images, Inc.

Vital Images, Inc., a Toshiba Medical Systems Group Company, is a leading provider of health imaging informatics solutions, including advanced visualization, enterprise image viewing solutions and business intelligence technology, designed to help healthcare organizations deliver exceptional care while optimizing resources across multi-facility organizations. The company's solutions are scalable to meet the unique needs of hospitals and imaging centers and are accessible throughout the enterprise anytime and anywhere. For more information, visit www.vitalimages.com or join the conversation on Twitter, LinkedIn and YouTube.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.